arq 197

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

ArQule Joins Forces with Daiichi Sankyo to Fight Cancer

Eben Tessari submits: ArQule and Daiichi Sankyo announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. One agreement covers the license of ARQ 197 and the other is an R&D agreement. ARQ...

Tags: Agreement, Cancer, Seeking Alpha, Eben Tessari, ARQ 197, ArQule Inc., Biotech

External links 2008-11-11

Additional Resources

Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm c-Met Inhibition in Tumors with ARQ 197, Under Development by ArQule

CHICAGO -- Investigators today presented data from a Phase 1, dose-escalation trial with ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase under development by ArQule, Inc. (NASDAQ: ARQL). These data demonstrate that the compound is safe and well tolerated at oral doses up to 300 milligrams mg...

Tags: ArQule Inc., Asco Plc., Company

Research articles 2008-06-01

ArQule Inc. Q1 2008 Earnings Call Transcript

Question-and-Answer SessionOperator Operator Instructions. Our first question comes from the line of from inaudible with Needham & Company. Unidentified Analyst Hi, good morning. This is inaudible from Needham & Company. My first question is clinical, in terms for ARQ 197 single agent versus combination trials, what do you think...

Tags: ArQule Inc.

Earnings calls 2008-05-12

ArQule, Inc. Q3 2008 Earnings Call Transcript

Question-and-Answer SessionOperator Operator Instructions. First question comes from the line of Mark Monane of Needham & Company. Mark Monane - Needham & Company Thanks for taking our questions. Congratulations on your progress, a very exciting way to start the week. Peter Lawrence Thank you, Mark. Mark Monane -...

Tags: Patient, Call Transcript, Needham & Co., Earnings, ArQule Inc., Lung Cancer, Seeking Alpha

Earnings calls 2008-11-10

ArQule, Inc. Q4 2008 Earnings Call Transcript

Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Mark Monane from Needham & Company. Please proceed. Mark Monane – Needham & Company Thank you, good morning, and thank you for the comprehensive review. Brian Schwartz Good morning. Mark Monane – Needham & Company Glenn...

Tags: Call Transcript, Needham & Co., Earnings, Trial, ArQule Inc., Trial Design, Seeking Alpha

Earnings calls 2009-03-05